Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 28, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
In this NeurologyLive® Peer Exchange, sleep experts C. Michael Gibson, Ashgan A. Elshinawy, and Nathaniel F. Watson share resources for the treatment of sleep disorders.
Using a cohort of more than 2000 pregnancies, the data, presented at the 2022 ECTRIMS Congress, showed an extremely rare number of major congenital anomalies while on ocrelizumab, as most patients underwent live birth with no issue.
In the latest edition of our in-depth Q&A series, the neurologist at Allegheny Health Network’s Neuroscience Institute provided perspective on a new phase 3 trial assessing fenebrutinib, an investigational BTK inhibitor for relapsing multiple sclerosis.
Fan Nils Yang, PhD, postdoctoral researcher, University of Maryland, provides greater detail on the observational cohort study he did with colleagues, where they identified a link between neurocognitive function in children and insomnia.
Experts in neurology including Michael Levy, MD, PhD; Mitzi Williams, MD, and others, share their experiences with how patients with NMOSD are utilizing health care, and helping patients achieve optimal care.